Elena Monzón Manzano, María Teresa Álvarez Román, Raúl Justo Sanz, Hosvan y Fernández Bello, Diana Hernández, Mónica Martín Salces, Larissa Valor, Isabel Rivas Pollmar, Nora V. Butta1 and Víctor Jiménez Yuste.
British Society for Haematology and John Wiley & Sons LtdBritish Journal of Haematology, 2020, 189, 943–953 – 16 january 2020.
Multifactorial mechanisms leading to diminished platelet counts in immune thrombocytopaenia (ITP) might condition the ability of patients with ITP to respond to treatments.
Examining their platelet and immune features, we aimed to detect singular characteristics of patients with ITP who do not respond to any treatment.
We studied patients with chronic primary ITP who had been without treatment, or untreated (UT-ITP), for at least six months; included were responders to agonists of thrombopoietin receptors (TPO-RA), patients who showed no response to first- and second-line treatments (NR-ITP), and healthy controls.
Platelets from NR-ITP patients exposed a reduced amount of sialic acid residues.
Increased loss of platelet surface sialic acid residues was associated with increased platelet apoptosis.
NR-ITP patients had an increased fraction of naive lymphocyte (L) B cells and a reduced LTreg (Lymphocyte T-regulator) subset.
They also presented an anomalous monocyte and NK (Natural Killer) cells distribution.
TPO-RA-treated patients seemed to recover an immune homeostasis similar to healthy controls.
In conclusion, our results indicate a severe deregulation of the immune system of NR-ITP.
The inverse correlation between loss of sialic acid and LTreg count suggests a potential relationship between glycan composition on the platelet surface and immune response, positing terminal sugar moieties of the glycan chains as aetiopathogenic agents in ITP.